- Home
- HOLO vs NLSP Comparison
HOLO vs NLSP Comparison
Compare HOLO & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOLO
- NLSP
- Stock Information
- Founded
- HOLO 2018
- NLSP 2015
- Country
- HOLO China
- NLSP Switzerland
- Employees
- HOLO N/A
- NLSP N/A
- Industry
- HOLO Computer Software: Programming Data Processing
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- HOLO Technology
- NLSP Health Care
- Exchange
- HOLO Nasdaq
- NLSP Nasdaq
- Market Cap
- HOLO 66.3M
- NLSP 12.4M
- IPO Year
- HOLO N/A
- NLSP 2021
- Fundamental
- Price
- HOLO $5.04
- NLSP $2.18
- Analyst Decision
- HOLO
- NLSP
- Analyst Count
- HOLO 0
- NLSP 0
- Target Price
- HOLO N/A
- NLSP N/A
- AVG Volume (30 Days)
- HOLO 1.5M
- NLSP 193.3K
- Earning Date
- HOLO 08-10-2023
- NLSP 10-17-2025
- Dividend Yield
- HOLO N/A
- NLSP N/A
- EPS Growth
- HOLO N/A
- NLSP N/A
- EPS
- HOLO 13.81
- NLSP N/A
- Revenue
- HOLO $44,840,587.00
- NLSP N/A
- Revenue This Year
- HOLO N/A
- NLSP N/A
- Revenue Next Year
- HOLO N/A
- NLSP N/A
- P/E Ratio
- HOLO $0.35
- NLSP N/A
- Revenue Growth
- HOLO 37.10
- NLSP N/A
- 52 Week Low
- HOLO $4.16
- NLSP $1.30
- 52 Week High
- HOLO $375.20
- NLSP $6.97
- Technical
- Relative Strength Index (RSI)
- HOLO 56.30
- NLSP 50.45
- Support Level
- HOLO $4.42
- NLSP $1.88
- Resistance Level
- HOLO $5.25
- NLSP $2.02
- Average True Range (ATR)
- HOLO 0.34
- NLSP 0.13
- MACD
- HOLO 0.08
- NLSP -0.01
- Stochastic Oscillator
- HOLO 79.35
- NLSP 58.65
About HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.